Copyright
©The Author(s) 2021.
World J Clin Cases. Aug 6, 2021; 9(22): 6178-6200
Published online Aug 6, 2021. doi: 10.12998/wjcc.v9.i22.6178
Published online Aug 6, 2021. doi: 10.12998/wjcc.v9.i22.6178
Agent | Pharmaceutical property | Mechanism of action | Molecular effects on the liver | Molecular effects on lung | Approved indication(s) | Ref. |
Tocilizumab | IL-6 receptor-blocking agent | Reduced the expression of TNF-α and IL-10, downregulated inflammasome activation, and inhibited monocyte phagocytic activity, thereby suppressing the cytokine storm | Mild-to-moderate elevation in transaminases and drug-induced liver injury | Reduced the inflammation of lung tissue | Clinical trial stage | [110,141,142] |
Remdesivir | Antiviral drug | RNA-dependent RNA polymerase inhibitor (Adenosine analog) | Transaminases↑ Bilirubin↑ | Virus lung titers↓, lung hemorrhage↓, and improved pulmonary function | Approved to treat COVID-19 | [126,143] |
Oseltamivir | Antiviral drug | Neuraminidase inhibitor; inhibits the release of progeny virus from infected host cells | Transaminases↑ Bilirubin↑(Rare) | Interleukin IL-1β↓, TNF-α↓, IL-4↓, IFN-γ↓ | Approved for Influenza A and B | [144,145] |
Umifenovir (Arbidol) | Antiviral drug | Spike protein/ACE2 membrane fusion inhibitor; inhibits viral entry into target cells and stimulates the immune response | Transaminase↑ | Viral attachment to ACE2↓ | Clinical trial stage | [146] |
Lopinavir-Ritonavir | Antiviral drug | Antiretroviral protease inhibitor; disruption of viral entry | Golgi fragmentation↑, organelle stress response↑, hepatic injury↑ | p53 DNA damage response activation↑ | Approved for treatment of HIV | [147-149] |
Bicyclol | Antiviral compound candidate | Directly interacts with viral membranes and minimizes the host’s inflammatory response | Transaminases↓, hepatic triglyceride↓ | Attenuates LPS- acute lung injury | Approved for treatment of liver injury | [150,151] |
Ribavirin (plus IFN-α) | Antiviral drug | Inhibits viral RNA-dependent RNA polymerase (Guanine analog) | Transaminase↓, liver histological damage↓, liver inflammation↓ | Improved survival in patients with severe MERS-CoV infection | Approved for some viral diseases including hepatitis C, has limited value in treatment of COVID-19 | [152,153] |
Favipiravir | Antiviral drug | RNA-dependent RNA polymerase inhibitor | Abnormal liver function test (transaminase↑) | Viral load in the lungs↓, pulmonary tissue inflammation ↓ | Approved in some countries to treat influenza, Ebola, and noroviruses | [154,155] |
Chloroquine and hydroxychloroquine | Antimalarial medication | Inhibits viral fusion and entry into the cell | IL-6↓, TNF-α↓, NF-kB expression↓, liver tissue apoptosis↓ liver inflammation↓ | Lung inflammation↓, oxidative stress↓, pulmonary tissue fibrosis↓ | FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 | [156-158] |
Probiotics | Live microorganisms | Preventive effects on bacterial and viral infection | Hepatic inflammation↓, transaminases↓, TNF-α↓, ameliorating liver injury and improve liver function | Suppress lung inflammation, preventing effects on acute respiratory tract infections | Approved as dietary supplements | [159-161] |
N-Acetyl-Cysteine | Antioxidant agent | Precursor of reduced glutathione and mucolytic agent | Liver lactate↓, improve liver function | Inhibition of ACE activity, inhibit virus replication, pulmonary inflammation↓ | Approved for use in humans | [162,163] |
Glycyrrhizic acid | Natural triterpenoid saponin isolated from Glycyrrhiza spp | Anti-inflammatory, antioxidative, antiviral compound | Oxidative stress↓, apoptosis↓ in the liver tissue | Inhibited the replication and penetration into cells of the SARS-associated coronavirus, IL-33↓ | Approved as a food additive | [164,165] |
Vitamin E | Fat-soluble vitamin (alpha-tocopherol) | Antioxidant and immunomodulatory agent | ROS↓, GSH↑, NF-κB activation ↓, inflammation↓, fibrosis↓, transaminase↓ | Oxidative stress↓, NO and COX activity↓, T cell proliferation↑ | Approved as dietary supplements | [9,166,167] |
Vitamin A | Fat-soluble vitamin (all-trans-retinol) | Antioxidant and immunomodulatory agent | Transaminase↓, IL-10↑, NF-κb activation ↓, TNF-α↓ | IL1-β↓, Oxidative stress↓, improved pulmonary function | Approved as dietary supplements | [165,166] |
Vitamin D | Fat-soluble secosteroids (cholecalciferol) | Reduced viral entry and replication, attenuated inflammation | Modulated liver inflammation and fibrogenesis | TNF-α↓, IFNγ↓, GSH↑, improved pulmonary function | Approved as dietary supplements | [166,168,169] |
Vitamin C | Water-soluble vitamin (Ascorbic acid) | Cofactor for a number of enzymatic reactions; antioxidant | Transaminase↓, SOD↑, GSH↑, oxidative stress↓, TNF-α↓ | TNFα↓, IL-1β ↓, IL-8↓, NF-κB activation↓, inflammation↓ | Approved as dietary supplements | [166,170] |
Zinc | Dietary mineral | Anti-inflammatory and antioxidant micronutrient | Decreased pro-inflammatory cytokine production, oxidative stress↓, hepatic tissue apoptosis↓, | Attenuated lung tissue inflammation, TNF-α↓, IL-6↓, IL-1β↓, interferon-γ↑, IL-2↑ | Approved as dietary supplements | [171,172] |
Mg | Dietary mineral | Anti-inflammatory and antioxidant micronutrient | Liver fibrosis↓, IL-6↓, TNF-α↓, inhibited the NF-κB pathway, transaminase↓ | IL-6↓, IL-1β↓, NF-κB activation↓, COX-2 activity↓, prostaglandin E2↓, lung tissue oxidative stress↓ | Approved as dietary supplements | [173,174] |
Copper | Dietary mineral | Antiviral activity through damage in virus envelope and surface spikes and destruction of the viral genomes | Ceruloplasmin↑, inflammation↓, IL-6↓, oxidative stress↑ | Viral replication↓, virus particles released from infected cells↓, viral entry↓ | Approved as dietary supplements | [175,176] |
Dexamethasone | Corticosteroid medication | Reduced aggressive inflammatory response | VLDL↑, HDL↑, IL-1β↓, IL-2↓, TNF-α↓, interferon-γ↓, prostaglandins production↓, liver inflammation↓, prevented the liver fibrosis | Pulmonary inflammation↓, NF-κB activity↓, oxidative markers↓, lung tissue fibrosis↓, mortality in patients with severe COVID-19 disease↓ | WHO-approved treatment for COVID-19 | [177,178] |
- Citation: Sivandzadeh GR, Askari H, Safarpour AR, Ejtehadi F, Raeis-Abdollahi E, Vaez Lari A, Abazari MF, Tarkesh F, Bagheri Lankarani K. COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges. World J Clin Cases 2021; 9(22): 6178-6200
- URL: https://www.wjgnet.com/2307-8960/full/v9/i22/6178.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i22.6178